

CURRICULUM VITAE

NAME: **Jean B. Nachega, MD, PhD,
MPH, DTM&H, FRCP**

BUSINESS ADDRESS: Department of Epidemiology,
Graduate School of Public Health
University of Pittsburgh
A528 Crabtree Hall
130 DeSoto Street
Pittsburgh, PA 15261
Phone: 410-800 7803
Fax: 412-624 3737
E-mail: jbn16@pitt.edu

EDUCATION AND TRAINING

Undergraduate

1982-1985	Univ. of Namur Namur, Belgium	BSc, 1985	Bio-Chemistry
-----------	----------------------------------	-----------	---------------

Graduate

1985-1989	Univ. of Louvain Brussels, Belgium	MD, 1989	Medicine
1998-1999	Johns Hopkins Univ. Baltimore, MD, USA	MPH, 1999	Epidemiology & International Health
2000-2001	London School of Hygiene & Tropical Medicine, UK	DTM&H	Tropical Medicine & Public Health
2004-2008	Univ. of Cape Town, South Africa	PhD	Pharmaco- Epidemiology

Post-Graduate

1989-1995	Univ. of Louvain, Brussels, Belgium	Residency	Internal Medicine
1996-1997	Univ. of Louvain Brussels, Belgium	Fellowship	Infectious Diseases
2009-2010	Harvard School of Public Health, Boston, MA, Belgium	Fellowship	Biostatistics in AIDS Research

APPOINTMENTS AND POSITIONS

Academic

1999-2001	Research Associate	Dept. of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2001-2007	Assistant Scientist	Dept. of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2007-2012	Associate Scientist	Dept. of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2008-present	Professor Extraordinary & Part-time Director, Center for Infectious Diseases	Dept. of Medicine, Stellenbosch University, Faculty of Medicine, Cape Town, South Africa
2008-present	Honorary Full Professor of Medicine	Dept. of Medicine, University of Cape Town, Faculty of Medicine, Cape Town, South Africa
2009-present	Visiting Professor	Dept. of Medicine, University of Liege, Liege, Belgium
2009-2010	Senior Research Fellow	Dept. of Biostatistics, Harvard School of Public Health, Boston, MA, USA
2012-present	Associate Professor of Epidemiology	Dept. of Epidemiology, Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
2012-present	Adjunct Associate Professor of Epidemiology and International Health	Depts. of Epidemiology & International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2015-present	Visiting Professor of Infectious Diseases/VIH-SIDA	Université Evangélique en Afrique Bukavu, Democratic Republic of the Congo

CERTIFICATION AND LICENSURE

Specialty Certification

1994-present	Specialist in Internal Medicine. OM# 85142-560	Belgian Board of Internal Medicine
--------------	---	---------------------------------------

Medical or Other Professional Licensure

Medical Practitioner for Post-Graduate Studies/Research	Health Professions Council of South Africa (HPCSA) MP 0513059	Pretoria, South Africa
---	---	------------------------

MEMBERSHIP IN PROFESSIONAL AND SCIENTIFIC SOCIETIES

1999-present	American Society of Tropical Medicine and Hygiene (ASTMH) www.astmh.org
1999-present	Infectious Diseases Society of America (IDSA) www.idsociety.org
2007-present	International AIDS Society (IAS) www.iasociety.org
2008-present	International Association of Providers in AIDS Care (IAPAC) www.iapac.org
2008-present	Southern Africa HIV Clinician Society (SAHIVSoc) www.sahivsoc.org
2008-present	Member elect, Academy of Sciences of South Africa www.assaf.co.za
2013-present	World Health Organization (WHO) HIV Treatment Guidelines Expert Panel www.who.int
2012-present	US Centers for Diseases Control (CDC) Global Health Expert Panel www.cdc.gov

- 2013-present NIH/NIAID AIDS Clinical Trial Group (ACTG), Tuberculosis Host-Directed Therapies (HDT) Working Group <https://actgnetwork.org/>
- 2014-present Fellow, Royal College of Physicians, Edinburgh, UK www.rcpe.ac.uk
- 2015-present Bill and Melinda Gates Foundation Optimizing HIV Treatment Cascade in Resource-Limited settings Expert Panel. www.gatesfoundations.org

HONORS

- 1985 Cum Laude, University of Namur, Namur, Belgium. www.unamur.be
- 1989 Cum Laude, University of Louvain, Brussels, Belgium. www.uclouvain.be
- 1998 Stelios M. Stelson Scholarship MPH Award, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. www.jhsph.edu
- 1998 Dikembe Mutombo African Education Scholarship Award, Dikembe Mutombo Foundation. www.dmf.org
- 1999 MPH Study Recognition Award For Outstanding Services, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. www.jhsph.edu
- 2003, 2005, 2006 International Travel Scholarship Award to attend and speak at the Annual Conference on Retroviruses and Opportunistic Infections (CROI), in 2003 & 2005 in Boston, MA, USA and 2006 in Denver, CO, USA www.croiconference.org/
- 2008 Member Elect, Delta Omega Public Health Honor Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA www.jhsph.edu/alumni/alumni-associations/delta-omega/

- 2009 John McGoldrick Fellowship in Biostatistics of AIDS Research, Harvard School of Public Health, Boston, MA, USA.
www.hsph.harvard.edu/biostats/mcgoldrick
- 2015 AIDS Journal Highly Cited Award in 2014: Clinical Science. Nachega et al. AIDS 2012 Oct 23;26 (16):2039-52. PMID: 22951634. www.aidsonline.org

PROFESSIONAL ACTIVITIES

1. Teaching

1.1. Teaching at University of Pittsburgh

a. Courses Taught

Years Taught	Course Number: Title	Hours of Lecture, credits Average Enrollment	Role in course Primary/Coordinator
2012 to present	EPIDEM 2166: Global Control of HIV/AIDS and Tuberculosis	4 hours/week, Spring Term 1 credit, 7 students	Primary Instructor

b. Other Teaching (lectures, tutorials and continuing education courses)

Date(s)	Type of Teaching	Title
March 10, 2013	Lecture, EPIDEM 2160	Global Control of Tuberculosis
October 15, 2014	Lecture, ID Fellows Seminar	Control of HIV/AIDS through Test-and-Treat Strategy

Date(s)	Type of Teaching	Title
March 26, 2015	Lecture, EPIDEM 2250	Addressing the Achilles' heel in the HIV care continuum for the success of the test-and-treat strategy to achieve an AIDS-free generation
September 10, 2015	Lecture, EPIDEM 2250	Tuberculosis active case finding in HIV mother-to-child prevention program in Soweto, South Africa
Since 2015	Lecture, HIV/AIDS	Université Evangélique en Afrique, Bukavu République Démocratique du Congo

c. Supervision of Post-Doctoral Students, Residents, and Fellows

Dates Supervised	Name of Student	Position of Student
2012-13	Zachor, Haddas	Pitt 4 th Year School of Medicine Student

d. Mentoring of Graduate Students in Field Placements

Dates	Name of Student	Degree/Program Description	Field Site
June to August, 2015	Allison, Morris	MPH	Stellenbosch University, Cape Town, South Africa
June to August, 2015	Anna Maria, Evans	MPH	Stellenbosch University, Cape Town, South Africa

Name of Student	Degree Awarded, Year	Type of Document and Title
Daniel Stein	MHS, 2002	Essay; “Knowledge, Attitudes, Beliefs and Practices to and Antiretroviral Therapy Adherence in HIV-infected Adults in Soweto, South Africa”

Dates	Name of Student	Degree/Program Description	Field Site
June to August, 2017	Kelsea LaSorda	MPH	Stellenbosch University, Cape Town, South Africa
June to August, 2017	Jenna Nelson	MPH	Stellenbosch University, Cape Town, South Africa

1.2. Teaching at Johns University, Bloomberg School of Public Health, Departments of Epidemiology and International Health

a. Teaching (lectures, tutorials and continuing education courses)

Date(s)	Type of Teaching	Title
2009 to present	Lecture, Course#340.659.11: Advanced Issues in HIV Epidemiology	HIV Prevention, Treatment and Care in Africa
2009 to present	Lecture, Course#223.666.01: Public Health and Medicine in the Tropics	HIV and Tuberculosis in the Tropics
2005-2012	Lecture, Course# 340.640.10: Global Disease Control Programs and Policies	HIV/AIDS in Africa
2003-2012	Lecture, Course#223. 682.01: Clinical Aspects of Tropical Diseases	Global Control Aspects of Lymphatic Filariasis

b. Major Advisor for Graduate Student Essays, Theses, and Dissertations

Dara Lehman	MHS, 2002	Essay; “Adherence to Antiretroviral Therapy in HIV-infected Adults , Soweto, South Africa”
Damilola Walker	MHS, 2004	Essay; “The Prospect for An Effective HIV Vaccine: Challenges and Opportunities”
Andrea de Luca	MHS, 2005	Essay; “Treatment-Supporter to Improve Adherence to Antiretroviral Therapy in Africa”
Melanie Lo	MHS, 2005	Essay; “Adherence to Antiretroviral Therapy Assessed by Pharmacy-Claim Improve Survival in HIV-infected South African Adults”
Jana Goins	MHS, 2006	Essay; “Antiretroviral Therapy and Virologic Outcomes in HIV-infected South African Adults”
Helizabeth Hazel	MHS, 2007	Essay; “Directly Observed Therapy for Antiretroviral Therapy: Acceptability and Feasibility in HIV-infected South African Adults”
Amanda Selin	MHS, 2007	Essay; “Association of Stigma and Sub-Optimal Antiretroviral Therapy Adherence in HIV-infected South African Adults”
Vikash Parekh	MHS, 2008	Essay; “Tuberculosis-HIV Co-Infection: Control Strategies in South Africa”
Sarah Wampold	MHS, 2009	Essay; “Antiretroviral Therapy Adherence in Pregnancy and Post-Partum HIV-infected South Africans”
Fiona Havers	MD, MPH 2010	Dissertation; “Tuberculosis-Immune Reconstitution Inflammatory Syndrome: Incidence, Risk Factors and Outcomes in HIV-infected Adults: A Cohort Study in Cape Town, South Africa”
David Dowdy	MD, PhD 2011	Dissertation; “Evaluation of Diagnostic Testing for Tuberculosis in High HIV & TB Burden Countries”

Melissa Roskoski	MHS 2011	Essay; “Are Gene Polymorphisms on Chromosome 22 Risk Factors for HIV Associated Nephropathy in South African Adults: A Case-Control Study”
Ethel Nakimuli Mpungu	PhD 2012	Dissertation; “Lifetime Depressive Disorders and Adherence to Antiretroviral Therapy in HIV-Infected Adults: A Case-Control Study”

d. Service on Master’s or Doctoral Committees

Dates Served	Name of Student	Degree Awarded	Title of Dissertation/Essay
2008-11	Homaira Hanif	PhD	“Multidimensional Influences on Antiretroviral Adherence and Consistent Condom Use Among People Living With HIV in Rio de Janeiro, Brazil”

f. Supervision of Post-Doctoral Students, Residents, and Fellows

Dates Supervised	Name of Student	Position of Student
2010	Fiona Havers	Resident in Internal Medicine

g. Mentoring of Graduate Students in Field Placements

Dates	Name of Student	Degree/Program Description	Field Site
Summer 2002	Daniel Stein	MHS	Baragwanath Hospital, Soweto, South Africa
	Dara Lehman	MHS	
Summer 2004	Damilola Walker	MHS	AIDS Vaccine Initiative, Uganda
Summer 2005	Andrea de Luca	MHS	Univ. of Cape Town, South Africa
	Melanie Lo	MHS	
Summer 2005	Virginia Wood	MHS	Univ. of Cape Town, South Africa

Dates	Name of Student	Degree/Program Description	Field Site
Summer 2006	Sangini Shah	MD	Univ. of Cape Town, South Africa
Summer 2006	Jana Goins	MHS	Univ. of Cape Town, South Africa
Summer 2007	Elizabeth Hazel Amanda Selin	MHS MHS	Univ. of Cape Town, South Africa
Summer 2007	Nathan Naussbaum	MD, MPH	Univ. of Cape Town, South Africa
Spring 2007	David Dowdy	MD, PhD	Univ. of Cape Town, South Africa
Summer 2008	Vikash Parekh	MHS	Univ. of Cape Town, South Africa
Summer 2009	Sarah Wampold	MHS	Univ. of Cape Town, South Africa
Summer 2010	Tiki Firdu	MD	Univ. of Cape Town, South Africa
Summer 2010	Fiona Havers	MD, MPH	Univ. of Stellenbosch, South Africa
Summer 2011	Melissa Roskoski	MHS	Univ. of Stellenbosch, South Africa

1.3. Teaching at Stellenbosch University, Cape Town, South Africa

a. Courses Taught

Years Taught	Course Number: Title	Hours of Lecture, credits Average Enrollment	Role in course Primary/Coordinator
2008 to present	Infectious Diseases Epidemiology	8 hours/week, Winter Term 4 credits, 20 students	Primary Instructor

b. Major Advisor for Graduate Student Essays, Theses, and Dissertations

Name of Student	Degree Awarded, Year	Type of Document and Title
Fidele Mukinda	MSc Epi, 2011	MSc Dissertation; “Rise in Rifampicin-Monoresistant Tuberculosis in Western Cape, South Africa: Risk Factors and Outcomes”
Ingrid Eshun-Wilson	MSc Epi, 2012	MSc Dissertation; “Risk Factors and Outcomes for TB in HIV-infected South African gold miners”
Remi Adeniyi	MScClinEpi, 2012	MSc Dissertation; “Prevalence of Chronic Kidney Disease Among Teachers in the Western Cape Province, South Africa”
Gert Van Zyl	PhD Virology, 2013	PhD Dissertation; “Antiretroviral Therapy Drug Resistance in mother-to-child HIV Prevention Program in the Western Cape Province, South Africa”
Michelle Zeier	PhD Epi, 2011	PhD Dissertation; “Combination Antiretroviral Therapy Reduces The Detection Risk of Cervical Human Papilloma Virus Infection in Women Living With HIV”
Andre Bula Bula	MScClinEpi, Graduated March 2015	MSc Dissertation; “Prevalence, Risk Factors and Outcomes of Rifampicin-Resistant Tuberculosis in Bukavu, Democratic Republic of the Congo”
Liliane Byamungu	MScClinEpi, Graduated March 2017	MSc Dissertation; “Prevalence, Risk Factors and Outcomes Associated with Late HIV diagnosis in Children with Tuberculosis co-Infection in Cape Town, South Africa: A Cohort Study”

Patrick Katoto	MScClinEpi, Graduated March 2017	MSc Dissertation; “Antiretroviral Associated Cardiovascular and Metabolic Complications in HIV-infected Adults in Bukavu, DR Congo”
Ngoie Nkongolo	MScClinEpi, Graduated March 2017	MSc Dissertation; ‘Prevalence of renal dysfunction at 6- and 12-months after initiation of Tenofovir-containing regimen in HIV-infected adults at Themba Lethu Clinic, Johannesburg, South Africa’

c. Service on Master’s or Doctoral Committees

Dates Served	Name of Student	Degree	Title
2009-13	Elizabeth Lutge	PhD 2013	“Economic Support to Improve Tuberculosis Treatment Outcomes in South Africa: A Pragmatic Cluster-Randomized Controlled Trial.”
2010-14	Steve Innes	PhD 2014	“High prevalence of lipotrophy in pre-pubertal South African children on antiretroviral therapy: a cross-sectional study”
2010-14	Suereta Fortuin	PhD 2014	“Phosphoproteomics Analysis of a Clinical Mycobacterium Tuberculosis Beijing Isolate: Expanding The Mycobacterial Phosphoproteome Catalog”
2013-2016	Angela Dramowski	PhD 2016	“Determinants of Health Care Associated Infections Among Hospitalized Children at Tygerberg Hospital, Cape Town, South Africa”
2014 to present	Talitha Crowley	PhD Pending	“The Conceptualization & Measurement of Adolescent HIV Self-Management in A South African Context”

Dates Served	Name of Student	Degree	Title
2016 to present	Parvine B. Bisimwa	PhD Pending	“Etude épidémiologique et cartographie moléculaire des virus des hépatites virales chroniques et de leur co-infection avec le virus de l’immunodéficience humaine au Sud-Kivu à l’est de la République Démocratique du Congo (RDC)”
2016 to present	Theophile M. Kashosi	PhD Pending	“Diagnostic précoce du nourrisson à l'aide de GeneXpert VIH: faisabilité, impact et résultats à Bukavu, République Démocratique du Congo”
2017 to present	Patrick DM Katoto	PhD Pending	“Household Air Pollution and Risk of Tuberculosis in HIV Infected Patients in the Democratic Republic of the Congo”
2013 to present	Didier Tshialala Mukeba	PhD Pending	“Prévalence de l’hypertension artérielle, de l’obésité, de l’hypercholestérolémie et du diabète non-traités chez les personnes adultes non-infectées versus infectées par le VIH et sous trithérapie de première ligne à Mbuji-Mayi, République Démocratique du Congo”
2014 to present	Elisabeth Gonese	PhD graduation expected December 2017	“Comparative analysis of Biorad avidity assay and limiting antigen avidity in measuring HIV incidence”
2016 to present	Gareth Tarr	PhD Pending	“Biologic disease modifying anti-rheumatic drugs and tuberculosis in South African rheumatology patients”
2016 to present	Geoffrey Fatti	PhD Pending	“An evaluation of the effectiveness community-base care models, for HIV treatment and prevention programs in South Africa”

Dates Served	Name of Student	Degree	Title
2016 to present	Rory Leisegang	PhD Pending	“Outcomes and cost-effectiveness of different models of delivery of antiretroviral therapy”

2. Research and Training
a. Grants and Contracts Received

Principal Investigator

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
3/15/06 - 12/30/10	K23 AI 068582 DOT-HAART Regimens for HIV-Infected South African Adults	NIH/NIAID	\$130,446	75%
2/09/2010 - 12/31/2013; Non-Cost extension 12/31/2014	TA.08.40200.021 NSAIDs for Prevention of Tuberculosis-Immune Reconstitution Inflammatory Syndrome in HIV-Infected Adults: A Double-Bind Randomized Clinical Trial	European Developing Countries Partnership (EDCTP)	€85,138.65	25%
3/1/2010 - 2015; Cost Extension to 8/31/16	T84HA21652 Stellenbosch University Rural Medical Partnership Initiative	HRSA	\$2,000,000	25%
09/01-2016-09/01/2021	1D43TW010340-01 Pittsburgh-Stellenbosch University AIDS-comorbidities Training Research Program (Pitt-SU AICoTRP. Role: PI	NIH/FIC	\$500,000	23%

Co-Investigator on Grants

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
12/10/13 - 11/30/20	AI069521-08 Stellenbosch University Clinical Trial Unit for ACTG	NIH/NIAID	\$1,504,116	5%
05/09/14-03/31/19	D43 TW009753-01 Fogarty HIV Research Training Program, Mozambique	NIH/FIC	\$54,281	5%
04/01/15 - 03/31/20	1U2GGH001536-01 South African University-Based Technical Assistance to Improve the Quality of HIV/AIDS and Related Services	US CDC	\$1,200,000	10%
03/15/06-02/28/11	1R21 MH083592-01 Reliability of measurement tools for HIV Treatment Adherence in Malawi	NIH/NIMH	\$60,000	5%
01/01/00 – 01/01/05	R01 AI 01637 Novel TB Prevention Regimens for HIV-infected South African Adults	NIH/NIAID	\$694,574	80%
1/1/2002 - 1/1/2003	5P30AI042855-03 A Pilot Study of Knowledge, Attitudes and Beliefs About and Adherence to Therapies for HIV Infection in Soweto, South Africa. Role: PI on this pilot study; but co-I on the overall Hopkins CFAR program (PI: Dr. John Bartlett)	NIH/NIAID Through Johns Hopkins Center for AIDS Research (CFAR)	\$55,000	55%
1/09/03 - 9/30/07	R01 AI 55359 DOT-HAART Regimens for HIV-Infected South African Adults	NIH/NIAID	\$500,000	50%

3/15/10 - 03/30/15; 1yr cost- extension to 2016)	WT08753MA Southern Africa Consortium for Research Excellence (SACORE); co-Applicant and SACORE Program Director at Stellenbosch University. PI: Newton Kumwenda (2010-2014); Moffat Nyirenda (2014- 2016)	Wellcome Trust	\$1,500,000	10%
12/01/2017- 12/01/2019	Stellenbosch Univ. Rector Faculty Strategic Award; PI	Stellenbosch University	\$120,000	10%
05/09/2014- 03/31/2019	D43 TW009753-05; Pitt HIV Research Training Program in Mozambique	NIH/FIC	\$281,720	5%
1/1/2014- 11/30/2020	7UM1AI068636-13; AIDS Clinical Trial Group (Co-I)	NIH/NIAID	N/A	5%
04/30/2019- 03/31/2024	1D43TW010937-01A1; University of Pittsburgh HIV-Comorbidities Research Training Program in South Africa (PI)	NIH/FIC	\$301,237	15%
09/19/2018- 08/31/2023	1R25TW011217-01; African Association for Health Professions Education and Research (Multiple-PI)	NIH/FIC	\$944,587	20%

Grants to be Submitted

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
04/01/2020- 04/01/2025	mHealth and Peer- Support to Improve Maternal & Child HIV Outcomes During Pregnancy& Post- Partum in South Africa (R01) (PI)	NIH/NIAID	\$500,000	25%
09/01/2018- 1923	Case-Pitt Center for AIDS Research (CFAR) (U01) (co-I)	NIH/FIC	TBD	15%

Years Inclusive	Grant and/or Contract Number and Title	Source	Annual Direct Costs	% Effort
02/01/2020-02/01/2025	African Drug-Resistant Tuberculosis Research Training Program (ADR-TB RTP) (D43) (Multiple-PI)	NIH/FIC	\$300,000	10%
04/01/2020-04/01/2024	Consortium for Maternal and Child Implementation Science in Africa (Multiple-PI)	EDCTP	€1,000,000	20%
09/01/2020-09/01/2024	Intra-Africa Mobility Program	European Union	€500,000	10%

PUBLICATIONS

1. Selected Refereed Articles (From a total of 169)

1. Lesage V, Van Pee D, Luyx C, **Nachega JB**, Boutsen Y, Swine C. Septic arthritis caused by Haemophilus influenzae associated with endocarditis. Clin Rheumatol 1998; 17(4): 340-2.
2. **Nachega JB**, Vandercam B, d'Udekem Y, Verhelst R, Jacquet L, Dion R, Goenen M. Chronic dissection of the thoracic aorta in a patient with tuberculous pleuro-pericarditis. Acta Clin Belg Feb 1998; 53(1): 53-4.
3. Colebunders R, **Nachega J**, Van Gompel A. Antiretroviral treatment and travel to developing countries. Journal of Travel Medicine. 1999 Mar; 6 (1):27-31. PMID: 10071370.
4. Colebunders R, Verdonck K, **Nachega J**, Kothari P. Impact of new developments in antiretroviral treatment on AIDS prevention and care in resource-poor countries. AIDS Patient Care and STDs. 2000 May; 14 (5):251-7. PMID: 10833812.
5. **Nachega J**. Antiretroviral treatment in developing countries. The Hopkins HIV Report: A Bimonthly Newsletter For Healthcare Providers / Johns Hopkins University AIDS Service. 2002 Sep; 14 (5):10-1, 15. PMID: 12240641.
6. **Nachega JB**, Chaisson RE. Tuberculosis drug resistance: a global threat. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2003 Jan 15; 36:S24-30. PMID: 12516027.
7. **Nachega J**, Coetzee J, Adendorff T, Msandiwa R, Gray GE, McIntyre JA, Chaisson RE. Tuberculosis active case-finding in a mother-to-child HIV transmission prevention programme in Soweto, South Africa. AIDS (London, England). 2003 Jun 13; 17 (9):1398-400. PMID: 12799565.
8. **Nachega JB**, Stein DM, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, Karstaedt AS. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS research and human retroviruses. 2004 Oct; 20 (10):1053-6. PMID: 15585095.

9. **Nachega JB**, Lehman DA, Hlatshwayo D, Mothopeng R, Chaisson RE, Karstaedt AS. HIV/AIDS and antiretroviral treatment knowledge, attitudes, beliefs, and practices in HIV-infected adults in Soweto, South Africa. *Journal of acquired immune deficiency syndromes (1999)*. 2005 Feb 1; 38 (2):196-201. PMID: 15671805.
10. **Nachega JB**, Rombaux P, Weynand B, Thomas G, Zech F. Successful treatment of *Acanthamoeba* rhinosinusitis in a patient with AIDS. *AIDS Patient Care STDS* Oct 2005; 19(10): 621-5.
11. Wilson D, **Nachega J**, Morroni C, Chaisson R, Maartens G. Diagnosing smear-negative tuberculosis using case definitions and treatment response in HIV-infected adults. *The International Journal of Tuberculosis and Lung Disease: The Official Journal of The International Union Against Tuberculosis and Lung Disease*. 2006 Jan; 10 (1):31-8. PMID: 16466034.
12. Mills EJ, **Nachega JB**, Buchan I, Orbinski J, Attaran A, Singh S, Rachlis B, Wu P, Cooper C, Thabane L, Wilson K, Guyatt GH, Bangsberg DR. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. *JAMA: the journal of the American Medical Association*. 2006 Aug 9; 296 (6):679-90. PMID: 16896111.
13. Mills EJ, **Nachega JB**, Bangsberg DR, Singh S, Rachlis B, Wu P, Wilson K, Buchan I, Gill CJ, Cooper C. Adherence to HAART: a systematic review of developed and developing nation patient-reported barriers and facilitators. *PLoS medicine*. 2006 Nov; 3 (11):e438. PMCID: PMC1637123. PMID: 17121449.
14. Mills EJ, Singh S, Nelson BD, **Nachega JB**. The impact of conflict on HIV/AIDS in sub-Saharan Africa. *International Journal of STD & AIDS*. 2006 Nov; 17 (11):713-7. PMID: 17062170.
15. Mills EJ, **Nachega JB**. HIV infection as a weapon of war. *Lancet Infect Dis* Dec 2006; 6(12): 752-3.
16. **Nachega JB**, Knowlton AR, Deluca A, Schoeman JH, Watkinson L, Efron A, Chaisson RE, Maartens G. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. *Journal of acquired immune deficiency syndromes (1999)*. 2006 Dec 1; 43:S127-33. PMID: 17133196.
17. **Nachega JB**, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. *Annals of internal medicine*. 2007 Apr 17; 146 (8):564-73. PMID: 17438315.
18. Spinewine A, Swine C, Dhillon S, Lambert P, **Nachega JB**, Wilmotte L, Tulkens PM. Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial. *Journal of The American Geriatrics Society*. 2007 May; 55 (5):658-65. PMID: 17493184.
19. Mills EJ, **Nachega JB**. A wake-up call for global access to salvage HIV drug regimens. *Lancet* 09 Dec 2007; 370(9603): 1885-7.
20. Bisson GP, Gross R, Bellamy S, Chittams J, Hislop M, Regensberg L, Frank I, Maartens G, **Nachega JB**. Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. *PLoS medicine*. 2008 May 20; 5 (5):e109. PMCID: PMC2386831. PMID: 18494555.
21. **Nachega JB**, Hislop M, Dowdy DW, Gallant JE, Chaisson RE, Regensberg L, Maartens G. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. *AIDS (London, England)*. 2008 Oct 18; 22 (16):2117-25. PMCID: PMC2659649. PMID: 18832875.

22. Mills EJ, Kelly S, Bradley M, Mollon P, Cooper C, **Nachega J**. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis. *HIV medicine*. 2008 Nov; 9 (10):849-57. PMID: 18795965.
23. Eyawo O, **Nachega J**, Lefebvre P, Meyer D, Rachlis B, Lee CW, Kelly S, Mills E. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. *Clinical Ophthalmology (Auckland, N.Z.)*. 2009; 3:447-56. PMCID: PMC2724035. PMID: 19684868.
24. Mills EJ, Perri D, Cooper C, **Nachega JB**, Wu P, Tleyjeh I, Phillips P. Antifungal treatment for invasive *Candida* infections: a mixed treatment comparison meta-analysis. *Annals of Clinical Microbiology and Antimicrobials*. 2009; 8:23. PMCID: PMC2713200. PMID: 19558681.
25. **Nachega JB**, Hislop M, Nguyen H, Dowdy DW, Chaisson RE, Regensberg L, Cotton M, Maartens G. Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. *Journal of acquired immune deficiency syndromes (1999)*. 2009 May 1; 51 (1):65-71. PMCID: PMC2674125. PMID: 19282780.
26. Eshun-Wilson I, Plas HV, Prozesky HW, Zeier MD, **Nachega J**, Taljaard JJ. Combined antiretroviral treatment initiation during hospitalization: outcomes in South African adults. *J Acquir Immune Defic Syndr* 02 May 2009; 51(1): 105-6.
27. **Nachega JB**, Trotta MP, Nelson M, Ammassari A. Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications. *Current HIV/AIDS Reports*. 2009 Aug; 6 (3):121-9. PMID: 19589297.
28. Ford N, **Nachega JB**, Engel ME, Mills EJ. Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials. *Lancet*. 2009 Dec 19; 374 (9707):2064-71. PMID: 19954833.
29. **Nachega JB**, Mills EJ, Schechter M. Antiretroviral therapy adherence and retention in care in middle-income and low-income countries: current status of knowledge and research priorities. *Current opinion in HIV and AIDS*. 2010 Jan; 5 (1):70-7. PMID: 20046150.
30. **Nachega JB**, Leisegang R, Bishai D, Nguyen H, Hislop M, Cleary S, Regensberg L, Maartens G. Association of antiretroviral therapy adherence and health care costs. *Annals of internal medicine*. 2010 Jan 5; 152 (1):18-25. PMID: 20048268.
31. **Nachega JB**, Chaisson RE, Goliath R, Efron A, Chaudhary MA, Ram M, Morroni C, Schoeman H, Knowlton AR, Maartens G. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. *AIDS (London, England)*. 2010 Jun 1; 24 (9):1273-80. PMCID: PMC2888722. PMID: 20453627.
32. Sester M, Giehl C, McNerney R, Kampmann B, Walzl G, Cuchí P, Wingfield C, Lange C, Migliori GB, Kritski AL, Meyerhans A, for the **European Network for global cooperation in the field of AIDS and TB (EU-CO-Net) Working Group**. Challenges and perspectives for improved management of HIV/Myco**acterium tuberculosis** co-infection. *The European Respiratory Journal*. 2010 Dec; 36 (6):1242-7. PMID: 21119204.
33. **Nachega JB**, Rosenkranz B, Pham PA. Twice-daily versus once-daily antiretroviral therapy and coformulation strategies in HIV-infected adults: benefits, risks, or burden? *Patient Preference and Adherence*. 2011; 5:645-51. PMCID: PMC3259079. PMID: 22259241.
34. Mills EJ, Kanters S, Hagopian A, Bansback N, **Nachega J**, Alberton M, Au-Yeung CG, Mtambo A, Bourgeault IL, Luboga S, Hogg RS, Ford N. The financial cost of doctors emigrating from sub-Saharan Africa: human capital analysis. *BMJ (Clinical Research Ed.)*. 2011; 343:d7031. PMCID: PMC3223532. PMID: 22117056.

35. **Nachega JB**, Mugavero MJ, Zeier M, Vitória M, Gallant JE. Treatment simplification in HIV-infected adults as a strategy to prevent toxicity, improve adherence, quality of life and decrease healthcare costs. *Patient Preference and Adherence*. 2011; 5:357-67. PMID: 21845035.
36. Steele KT, Steenhoff AP, Newcomb CW, Rantleru T, Nthobatsang R, Lesetedi G, Bellamy SL, **Nachega JB**, Gross R, Bisson GP. Early mortality and AIDS progression despite high initial antiretroviral therapy adherence and virologic suppression in Botswana. *PloS One*. 2011; 6 (6):e20010. PMID: 21698283.
37. Bakanda C, Birungi J, Mwesigwa R, **Nachega JB**, Chan K, Palmer A, Ford N, Mills EJ. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda. *PloS One*. 2011; 6 (4):e19261. PMID: 21559441.
38. Bakanda C, Birungi J, Mwesigwa R, Ford N, Cooper CL, Au-Yeung C, Chan K, **Nachega JB**, Wood E, Hogg RS, Dybul M, Mills EJ. Association of aging and survival in a large HIV-infected cohort on antiretroviral therapy. *AIDS (London, England)*. 2011 Mar 13; 25 (5):701-5. PMID: 21160412.
39. **Nachega JB**, Rosenkranz B. Targeting tuberculosis and HIV/AIDS: a global progress report of a deadly partnership. *Infectious Disorders Drug Targets*. 2011 Apr; 11 (2):96-7. PMID: 21406055.
40. Zeier MD, **Nachega JB**. Targeting HIV: past, present and future. *Infectious Disorders Drug Targets*. 2011 Apr; 11 (2):98-114. PMID: 21406054.
41. Hong SY, **Nachega JB**, Kelley K, Bertagnolio S, Marconi VC, Jordan MR. The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention. *Infectious Disorders Drug Targets*. 2011 Apr; 11 (2):124-33. PMID: 21406052.
42. **Nachega JB**, Rosenkranz B, Simon G, Chaisson RE, Diacon A, Taljaard J. Management of adult active tuberculosis disease in era of HIV pandemic, current practices and future perspectives. *Infectious Disorders Drug Targets*. 2011 Apr; 11 (2):134-43. PMID: 21406051.
43. **Nachega JB**, Marconi VC, van Zyl GU, Gardner EM, Preiser W, Hong SY, Mills EJ, Gross R. HIV treatment adherence, drug resistance, virologic failure: evolving concepts. *Infectious Disorders Drug Targets*. 2011 Apr; 11 (2):167-74. PMID: 21406048.
44. van Zyl GU, van Mens TE, McIlleron H, Zeier M, **Nachega JB**, Decloedt E, Malavazzi C, Smith P, Huang Y, van der Merwe L, Gandhi M, Maartens G. Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. *Journal of Acquired Immune Deficiency Syndromes (1999)*. 2011 Apr; 56 (4):333-9. PMID: 21239995.
45. Wilson D, Mbhele L, Badri M, Morroni C, **Nachega J**, Chaisson RE, Maartens G. Evaluation of the World Health Organization algorithm for the diagnosis of HIV-associated sputum smear-negative tuberculosis. *The International Journal of Tuberculosis and Lung Disease : The Official Journal of The International Union Against Tuberculosis and Lung Disease*. 2011 Jul; 15 (7):919-24. PMID: 21682965.
46. Mills EJ, Bakanda C, Birungi J, Chan K, Ford N, Cooper CL, **Nachega JB**, Dybul M, Hogg RS. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. *Annals of Internal Medicine*. 2011 Aug 16; 155 (4):209-16. PMID: 21768555.
47. Nakimuli-Mpungu E, Musisi S, Katabira E, **Nachega J**, Bass J. Prevalence and factors

- associated with depressive disorders in an HIV+ rural patient population in southern Uganda. *Journal of Affective Disorders*. 2011 Dec; 135:160-7. PMID: 21851986.
48. **Nachega JB**, Morroni C, Chaisson RE, Goliath R, Efron A, Ram M, Maartens G. Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. Patient preference and adherence. 2012; 6:887-91. PMCID: PMC3526885. PMID: 23271897.
 49. Nakimuli-Mpungu E, Mojtabai R, Alexandre PK, Katabira E, Musisi S, **Nachega JB**, Bass JK. Cross-cultural adaptation and validation of the self-reporting questionnaire among HIV+ individuals in a rural ART program in southern Uganda. *HIV/AIDS (Auckland, N.Z.)*. 2012; 4:51-60. PMCID: PMC3346063. PMID: 22570575.
 50. Cooper CL, Druyts E, Thorlund K, **Nachega JB**, El Khoury AC, O'Regan C, Mills EJ. Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis. *Therapeutics and Clinical Risk Management*. 2012; 8:105-30. PMCID: PMC3307664. PMID: 22442631.
 51. Druyts E, Mills EJ, **Nachega J**, O'Regan C, Cooper CL. Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis. *Clinical and Experimental Gastroenterology*. 2012; 5:11-21. PMCID: PMC3304330. PMID: 22427726.
 52. Eshun-Wilson I, Taljaard JJ, **Nachega JB**. Sub-optimal CD4 T-lymphocyte responses among HIV infected patients who develop TB during the first year of ART. *Journal of AIDS & clinical research*. 2012 Jan 29; 3 (135). PMCID: PMC3308912. PMID: 22442755.
 53. Mukinda FK, Theron D, van der Spuy GD, Jacobson KR, Roscher M, Streicher EM, Musekiwa A, Coetzee GJ, Victor TC, Marais BJ, **Nachega JB**, Warren RM, Schaaf HS. Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa. *The International Journal of Tuberculosis and Lung Disease: The Official Journal of The International Union Against Tuberculosis and Lung Disease*. 2012 Feb; 16 (2):196-202. PMCID: PMC3712259. PMID: 22236920.
 54. Maher D, Harries AD, **Nachega JB**, Jaffar S. Methodology matters: what type of research is suitable for evaluating community treatment supporters for HIV and tuberculosis treatment? *Tropical Medicine & International Health: TM & IH*. 2012 Mar; 17 (3):264-71. PMID: 22171790.
 55. Uthman O, Mofenson LM, **Nachega JB**. Safety and effectiveness of efavirenz versus nevirapine-based regimens in resource-limited settings: evidence, clinical practice and modelling projections. *AIDS* 14 Mar 2012; 26(5): 639-41.
 56. Jordan MR, Bennett DE, Wainberg MA, Havlir D, Hammer S, Yang C, Morris L, Peeters M, Wensing AM, Parkin N, **Nachega JB**, Phillips A, De Luca A, Geng E, Calmy A, Raizes E, Sandstrom P, Archibald CP, Perriens J, McClure CM, Hong SY, McMahon JH, Dedes N, Sutherland D, Bertagnolio S. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011. *Clinical infectious diseases: an official publication of the Infectious Diseases Society of America*. 2012 May; 54: S245-9. PMCID: PMC3338313. PMID: 22544182.
 57. Young T, Abba K, Deeks JJ, Olliaro PL, Naing CM, Jackson SM, Takwoingi Y, Donegan S, Garner P, Bottieau E, Jacobs J, **Nachega JB**, Leeflang M. Cochrane Column * Rapid diagnostic tests can extend access of diagnostic services for uncomplicated Plasmodium falciparum malaria * Commentary: Rapid diagnostic tests for diagnosing uncomplicated Plasmodium falciparum malaria in endemic countries (R Int J Epidemiol Jun 2012; 41(3): 607-10).

58. Thompson MA, Mugavero MJ, Amico KR, Cargill VA, Chang LW, Gross R, Orrell C, Altice FL, Bangsberg DR, Bartlett JG, Beckwith CG, Dowshen N, Gordon CM, Horn T, Kumar P, Scott JD, Stirratt MJ, Remien RH, Simoni JM, **Nachega JB**. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an International Association of Physicians in AIDS Care panel. *Annals of internal medicine*. 2012 Jun 5; 156 (11):817-33, PMID: 22393036.
59. Zeier MD, Botha MH, van der Merwe FH, Eshun-Wilson I, van Schalkwyk M, la Grange M, Mason D, Louw M, **Nachega JB**. Progression and persistence of low-grade cervical squamous intraepithelial lesions in women living with human immunodeficiency virus. *Journal of lower genital tract disease*. 2012 Jul; 16 (3):243-50. PMID: 22460273.
60. **Nachega JB**, Hsu AJ, Uthman OA, Spinewine A, Pham PA. Antiretroviral therapy adherence and drug-drug interactions in the aging HIV population. *AIDS (London, England)*. 2012 Jul 31; 26: S39-53. PMID: 22781176.
61. Svensson E, van der Walt JS, Barnes KI, Cohen K, Kredo T, Huitema A, **Nachega JB**, Karlsson MO, Denti P. Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics. *British Journal of Clinical Pharmacology*. 2012 Sep; 74 (3):465-76. PMCID: PMC3477348. PMID: 22300396.
62. Murphy RA, Sunpath H, Castilla C, Ebrahim S, Court R, Nguyen H, Kuritzkes DR, Marconi VC, **Nachega JB**. Second-line antiretroviral therapy: long-term outcomes in South Africa. *Journal of acquired immune deficiency syndromes (1999)*. 2012 Oct 1; 61 (2):158-63. PMID: 22692090.
63. **Nachega JB**, Uthman OA, Anderson J, Peltzer K, Wampold S, Cotton MF, Mills EJ, Ho YS, Stringer JS, McIntyre JA, Mofenson LM. Adherence to antiretroviral therapy during and after pregnancy in low-income, middle-income, and high-income countries: a systematic review and meta-analysis. *AIDS (London, England)*. 2012 Oct 23; 26 (16):2039-52. PMID: 22951634.
64. Nakimuli-Mpungu E, Bass JK, Alexandre P, Mills EJ, Musisi S, Ram M, Katabira E, **Nachega JB**. Depression, alcohol use and adherence to antiretroviral therapy in sub-Saharan Africa: a systematic review. *AIDS and behavior*. 2012 Nov; 16 (8):2101-18. PMID: 22116638.
65. Mills FP, Ford N, **Nachega JB**, Bansback N, Nosyk B, Yaya S, Mills EJ. Earlier initialization of highly active antiretroviral therapy is associated with long-term survival and is cost-effective: findings from a deterministic model of a 10-year Ugandan cohort. *Journal of acquired immune deficiency syndromes (1999)*. 2012 Nov 1; 61 (3):364-9. PMID: 22766966.
66. **Nachega JB**, Uthman OA, Ho YS, Lo M, Anude C, Kayembe P, Wabwire-Mangen F, Gomo E, Sow PS, Obike U, Kusiaku T, Mills EJ, Mayosi BM, Ijsselmuiden C. Current status and future prospects of epidemiology and public health training and research in the WHO African region. *International journal of epidemiology*. 2012 Dec; 41 (6):1829-46. PMCID: PMC3535755. PMID: 23283719.
67. Zeier MD, **Nachega JB**, Van Der Merwe FH, Eshun-Wilson I, Van Schalkwyk M, La Grange M, Mason D, Louw M, Botha MH. Impact of timing of antiretroviral therapy initiation on survival of cervical squamous intraepithelial lesions: a cohort analysis from South Africa. *International journal of STD & AIDS*. 2012 Dec; 23 (12):890-6. PMID: 23258831.
68. Zeier MD, **Nachega JB**, Van Der Merwe FH, Eshun-Wilson I, Van Schalkwyk M, La Grange M, Mason D, Louw M, Botha MH. Impact of timing of antiretroviral therapy initiation on survival of cervical squamous intraepithelial lesions: a cohort analysis from South Africa. *International Journal of STD & AIDS*. 2012 Dec; 23 (12):890-6. PMID: 23258831.
69. Hong SY, Jerger L, Jonas A, Badi A, Cohen S, **Nachega JB**, Parienti JJ, Tang AM, Wanke C,

- Terrin N, Pereko D, Blom A, Trotter AB, Jordan MR. Medication possession ratio associated with short-term virologic response in individuals initiating antiretroviral therapy in Namibia. *PloS one*. 2013; 8 (2):e56307. PMID: 23509605.
70. Ndiaye M, Nyasulu P, Nguyen H, Lowenthal ED, Gross R, Mills EJ, **Nachega JB**. Risk factors for suboptimal antiretroviral therapy adherence in HIV-infected adolescents in Gaborone, Botswana: a pilot cross-sectional study. *Patient Preference and Adherence*. 2013; 7:891-5. PMID: 24049440.
 71. Chu R, Mills EJ, Beyene J, Pullenayegum E, Bakanda C, **Nachega JB**, Devereaux PJ, Thabane L. Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis. *AIDS Research and Therapy*. 2013; 10 (1):19. PMID: 23849301.
 72. **Nachega JB**, Mutamba B, Basangwa D, Nguyen H, Dowdy DW, Mills EJ, Katabira E, Nakimuli-Mpungu E. Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults. *Tropical medicine & international health: TM & IH*. 2013 Jan; 18 (1):53-7. PMID: 23136882.
 73. Druyts E, Dybul M, Kanters S, **Nachega J**, Birungi J, Ford N, Thorlund K, Negin J, Lester R, Yaya S, Mills EJ. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. *AIDS (London, England)*. 2013 Jan 28; 27 (3):417-25. PMID: 22948271.
 74. Duwell MM, Knowlton AR, **Nachega JB**, Efron A, Goliath R, Morroni C, Maartens G, Chaisson RE. Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. *AIDS patient care and STDs*. 2013 Feb; 27 (2):96-102. PMID: 23373664.
 75. Nakimuli-Mpungu E, Mojtabei R, Alexandre PK, Musisi S, Katabira E, **Nachega JB**, Treisman G, Bass JK. Lifetime depressive disorders and adherence to anti-retroviral therapy in HIV-infected Ugandan adults: a case-control study. *Journal of Affective Disorders*. 2013 Feb 20; 145 (2):221-6. PMID: 23017542.
 76. Mills EJ, Funk A, Kanters S, Kawuma E, Cooper C, Mukasa B, Odit M, Karamagi Y, Mwehira D, **Nachega J**, Yaya S, Featherstone A, Ford N. Long-term health care interruptions among HIV-positive patients in Uganda. *Journal of acquired immune deficiency syndromes (1999)*. 2013 May 1; 63 (1): e23-7. PMID: 23406979.
 77. Mills EJ, Funk A, Kanters S, Kawuma E, Cooper C, Mukasa B, Odit M, Karamagi Y, Mwehira D, **Nachega J**, Yaya S, Featherstone A, Ford N. Long-term health care interruptions among HIV-positive patients in Uganda. *Journal of Acquired Immune Deficiency Syndromes (1999)*. 2013 May 1; 63 (1): e23-7. PMID: 23406979.
 78. **Nachega JB**, Uthman O, Ho YS. Authors' response to: *Epidemiology and public health research productivity in Africa*. *Int J Epidemiol* Jun 2013; 42(3): 913-4.
 79. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, **Nachega JB**. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. *The Journal of infectious diseases*. 2013 Jun 15; 207: S49-56. PMID: 23687289.
 80. Gupta RK, Wainberg MA, Brun-Vezinet F, Gatell JM, Albert J, Sönnnerborg A, **Nachega JB**. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs. *The Journal of infectious diseases*. 2013 Jun 15; 207: S101-6. PMID: 23687287.
 81. Chu R, Mills EJ, Beyene J, Pullenayegum E, Bakanda C, **Nachega JB**, Devereaux PJ, Thabane

- L. Impact of tuberculosis on mortality among HIV-infected patients receiving antiretroviral therapy in Uganda: a prospective cohort analysis. *AIDS research and therapy*. 2013 Jul 13; 10 (1):19. PMID: 23849301.
82. Rosenkranz B, **Nachega JB**. Editorial: diagnosis and management of malaria: an updated report on a deadly disease of global impact. *Infectious Disorders Drug Targets*. 2013 Aug; 13 (4):215-6. PMID: 24410675.
 83. Botha P, Bottieau E, Uthman O, Obike U, **Nachega JB**. Update on diagnostic and treatment of uncomplicated and complicated malaria in adults and selected vulnerable populations. *Infectious Disorders Drug Targets*. 2013 Aug; 13 (4):278-91. PMID: 24387665.
 84. Kanters S, **Nachega J**, Funk A, Mukasa B, Montaner JS, Ford N, Bucher HC, Mills EJ. CD4 T-cell recovery after initiation of antiretroviral therapy in a resource-limited setting: a prospective cohort analysis. *Antiviral Therapy*. 2013 Aug 20. PMID: 23963170.
 85. **Nachega JB**, Uthman OA, Mills EJ, Quinn TC. Adherence to Antiretroviral Therapy for the Success of Emerging Interventions to Prevent HIV Transmission: A Wake up Call. *Journal of AIDS & Clinical Research*. 2013 Oct 22; 2012. PMCID: PMC3766967. PMID: 24032088.
 86. Marconi VC, Wu B, Hampton J, Ordóñez CE, Johnson BA, Singh D, John S, Gordon M, Hare A, Murphy R, **Nachega J**, Kuritzkes DR, Del Rio C, Sunpath and South Africa Resistance Cohort Study Team Group Authors H. Early warning indicators for first-line virologic failure independent of adherence measures in a South african urban clinic. *AIDS Patient Care and STDs*. 2013 Dec; 27 (12):657-68. PMID: 24320011.
 87. Wu P, Johnson BA, **Nachega JB**, Wu B, Ordonez CE, Hare AQ, Kearns R, Murphy R, Sunpath H, Marconi VC. The combination of pill count and self-reported adherence is a strong predictor of first-line ART failure for adults in South Africa. *Current HIV Research*. 2014; 12 (5):366-75. PMID: 25426940.
 88. Nakimuli-Mpungu E, Dowdy DW, **Nachega JB**. RE: Severe mental illness at ART initiation is associated with worse retention in care among HIV-infected Ugandan adults by JM Nachega et al. (2013), *TMIH* 18, pp 53–57. *Trop Med Int Health* Jan 2014; 19(1): 133-4.
 89. **Rwandan Research and Implementation Writing Group**. Building health research infrastructure in Rwanda. *The Lancet. Global Health*. 2014 Jan; 2 (1):e9-e10. PMID: 25104639. doi: 10.1016/S2214-109X(13)70144-X.
 90. Sherer R, Solomon S, Schechter M, **Nachega JB**, Rockstroh J, Zuniga JM. HIV Provider-Patient Communication Regarding Cardiovascular Risk: Results from the 2010 AIDS Treatment for Life International Survey. *Journal of The International Association of Providers of AIDS Care*. 2014 Apr 9. PMID: 24718379.
 91. Estrella MM, Moosa MR, **Nachega JB**. Editorial commentary: Risks and benefits of tenofovir in the context of kidney dysfunction in sub-Saharan Africa. *Clin Infect Dis* May 2014; 58(10): 1481-3.
 92. **Nachega JB**, Parienti JJ, Uthman OA, Gross R, Dowdy DW, Sax PE, Gallant JE, Mugavero MJ, Mills EJ, Giordano TP. Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials. *Clinical Infectious Diseases: An Official Publication of The Infectious Diseases Society of America*. 2014 May; 58 (9):1297-307. PMCID: PMC3982838. PMID: 24457345.
 93. **Nachega JB**, Uthman OA, Del Rio C, Mugavero MJ, Rees H, Mills EJ. Addressing the Achilles' Heel in the HIV Care Continuum for the Success of a Test-and-Treat Strategy to Achieve an AIDS-Free Generation. *Clinical Infectious Diseases: An Official Publication of The Infectious Diseases Society of America*. 2014 Jul 1; 59:S21-7. PMID: 24926028.

94. Mash RJ, de Villiers MR, Moodley K, **Nachega JB**. Guiding the development of family medicine training in Africa through collaboration with the Medical Education Partnership Initiative. *Academic Medicine: Journal of The Association of American Medical Colleges*. 2014 Aug; 89:S73-7. PMID: 25072584. doi: 10.1097/ACM.0000000000000328.
95. **Medical Education Partnership Initiative Principal Investigators**. Academic Medicine. Foreword. *Academic Medicine: Journal of The Association of American Medical Colleges*. 2014 Aug; 89:S1-2. PMID: 25072557. doi: 10.1097/ACM.0000000000000357.
96. Uthman OA, Magidson JF, Safren SA, **Nachega JB**. Depression and adherence to antiretroviral therapy in low-, middle- and high-income countries: a systematic review and meta-analysis. *Current HIV/AIDS Reports*. 2014 Sep; 11 (3):291-307. PMID: 25038748. doi: 10.1007/s11904-014-0220-1.
97. van Zyl GU, Frenkel LM, Chung MH, Preiser W, Mellors JW, **Nachega JB**. Emerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits. *AIDS (London, England)*. 2014 Nov 28; 28 (18):2643-8. PMID: 25493592. doi: 10.1097/QAD.0000000000000502.
98. Mandala WL, Cowan FM, Lalloo DG, Wilkinson RJ, Kelly P, Chidzonga MM, Michelo C, Gomo E, Bailey R, Simuyemba M, Musonda R, Nyirenda M, **Nachega JB**. Southern Africa consortium for research excellence (SACORE): successes and challenges. *Lancet Glob Health* Dec 2014; 2(12): e691-2. doi: 10.1016/S2214-109X(14)70321-3.
99. Mills EJ, Lester R, Thorlund K, Lorenzi M, Katherine M, Kanters S, Linnemayr S, Gross R, Calderon Y, Amico R, Thirumurthy H, Pearson C, Remien RH, Mbwagbau L, Thabane L, Chung MH, Wilson I, Liu A, Uthman OA, Simoni J, Bangsberg DR, Sani Y, Barnighausen T, Ford N, **Nachega JB**. Interventions to promote adherence to antiretroviral therapy in Africa: a network meta-analysis. *The Lancet HIV*. 2014 Dec; 1 (3):e104-e111. doi: [http://dx.doi.org/10.1016/S2352-3018\(14\)00003-4](http://dx.doi.org/10.1016/S2352-3018(14)00003-4).
100. **Nachega JB**, Uthman OA, Peltzer K, Richardson LA, Mills EJ, Amekudzi K, Ouédraogo A. Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysis. *Bulletin of The World Health Organization*. 2015 Jan 1; 93 (1):29-41. PMCID: PMC4271680. PMID: 25558105. doi: 10.2471/BLT.14.138149.
101. Zeier MD, Botha MH, Engelbrecht S, Machezano RN, Jacobs GB, Isaacs S, van Schalkwyk M, van der Merwe H, Mason D, **Nachega JB**. Combination antiretroviral therapy reduces the detection risk of cervical human papilloma virus infection in women living with HIV. *AIDS (London, England)*. 2015 Jan 2; 29 (1):59-66. PMID: 25387313. doi: 10.1097/QAD.0000000000000512.
102. Geng EH, Neilands TB, Thièbaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN. CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa. *International Journal of Epidemiology*. 2015 Feb; 44 (1):251-63. PMCID: PMC4339766. PMID: 25859596.
103. Lowenthal ED, Marukutira T, Tshume O, Chapman J, **Nachega JB**, Anabwani G, Gross R. Parental absence from clinic predicts human immunodeficiency virus treatment failure in adolescents. *JAMA Pediatrics*. 2015 May 1; 169 (5):498-500. PMCID: PMC4420689. PMID:

25822083. doi: 10.1001/jamapediatrics.2014.3785.
104. Nakimuli-Mpungu E, Wamala K, Okello J, Alderman S, Odokonyero, Mojtabai R, Mills EJ, Kanters S, **Nachega JB**, Musisi S. Group support psychotherapy for depression treatment in people with HIV/AIDS in northern Uganda: a single-centre randomised controlled trial. *The Lancet HIV*. 2015 Mar 31; 2 (5):e190-e199.
 105. Uthman OA, Okwundu C, Gbenga K, Volmink JA, Dowdy DW, Zumla A, **Nachega JB**. Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis. *Ann Intern Med*. 2015 Jul 7;163(1):32-9. doi: 10.7326/M14-2979. PMID:26148280
 106. **Nachega JB**, Skinner D, Jennings L, Magidson JF, Altice FL, Burke JG, Lester RT, Uthman OA, Knowlton AR, Cotton MF, Anderson JR, Theron GB. Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. *Patient Prefer Adherence*. 2016 Apr 28; 10:683-90. PMID:27175068
 107. **Nachega JB**, Mills EJ, Uthman OA, Renaud F, Mofenson LM. Preconception ART and preterm birth: real effect or selection bias? *Lancet HIV*. 2017 Apr;4(4):e150-e151. doi: 10.1016/S2352-3018(17)30051-6. PMID: 28359445
 108. Kanters S, Park JJ, Chan K, Socias ME, Ford N, Forrest JI, Thorlund K, Nachega JB, Mills EJ. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. *Lancet HIV*. 2017 Jan;4(1):e31-e40. doi: 10.1016/S2352-3018(16)30206-5. Epub 2016 Nov 16. PMID: 27863996
 109. Kanters S, Park JJ, Chan K, Ford N, Forrest J, Thorlund K, **Nachega JB**, Mills EJ. Use of peers to improve adherence to antiretroviral therapy: a global network meta-analysis. *J Int AIDS Soc*. 2016 Nov 30;19(1):21141. doi: 10.7448/IAS.19.1.21141. eCollection 2016. PMID:27914185
 110. Shubber Z, Mills EJ, **Nachega JB**, Vreeman R, Freitas M, Bock P, Nsanzimana S, Penazzato M, Appolo T, Doherty M, Ford N. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. *PLoS Med*. 2016 Nov 29;13(11):e1002183. doi: 10.1371/journal.pmed.1002183. eCollection 2016 Nov. Review.
 111. Zumla A, Rao M, Wallis RS, Kaufmann SH, Rustomjee R, Mwaba P, Vilaplana C, Yeboah-Manu D, Chakaya J, Ippolito G, Azhar E, Hoelscher M, Maeurer M; **Host Directed Therapies Network consortium**. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. *Lancet Infect Dis*. 2016 Apr;16(4):e47-63. doi: 10.1016/S1473-3099(16)00078-5. PMID: 27036359
 112. **Global Burden of Diseases Collaborators**. Burden of Diarrhea in the Eastern Mediterranean Region, 1990-2013: Findings from the Global Burden of Disease Study 2013. *Am J Trop Med Hyg*. 2016 Dec 7;95(6):1319-1329. Epub 2016 Oct 10. PMID: 27928080
 113. **Global Burden of Diseases Maternal Mortality Collaborators**. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. PMID: 27733286

114. **Global Burden of Diseases Child Mortality Collaborators.** Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1725-1774. doi: 10.1016/S0140-6736(16)31575-6. PMID: 27733285
115. **Global Burden of Diseases Risk Factors Collaborators.** Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1659-1724. doi: 10.1016/S0140-6736(16)31679-8. PMID: 27733284
116. **Global Burden of Diseases DALYs and HALE Collaborators.** Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1603-1658. doi: 10.1016/S0140-6736(16)31460-X. PMID: 27733283
117. **Global Burden of Diseases and Injury Incidence and Prevalence Collaborators.** Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. PMID: 27733282
118. **Global Burden of Diseases Mortality and Causes of Death Collaborators.** Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1459-44
119. **Global Burden of Diseases SDG Collaborators.** Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet*. 2016 Oct 8;388(10053):1813-1850. doi: 10.1016/S0140-6736(16)31467-2. Epub 2016 Sep 21. PMID: 27665228
Uthman OA, Okwundu C, Gbenga K, Volmink JA, Dowdy DW, Zumla A, **Nachega JB.** Optimal Timing of Antiretroviral Therapy Initiation for HIV-Infected Adults With Newly Diagnosed Pulmonary Tuberculosis. *Ann Intern Med*. 2015 Jul 7;163(1):32-9. doi: 10.7326/M14-2979. PMID:26148280
121. **Nachega JB,** Skinner D, Jennings L, Magidson JF, Altice FL, Burke JG, Lester RT, Uthman OA, Knowlton AR, Cotton MF, Anderson JR, Theron GB. Acceptability and feasibility of mHealth and community-based directly observed antiretroviral therapy to prevent mother-to-child HIV transmission in South African pregnant women under Option B+: an exploratory study. *Patient Prefer Adherence*. 2016 Apr 28;10:683-90. PMID:2717506
Nachega JB, Mills EJ, Uthman OA, Renaud F, Mofenson LM. Preconception ART and preterm birth: real effect or selection bias? *Lancet HIV*. 2017 Apr;4(4):e150-e151. doi: 10.1016/S2352-3018(17)30051-6. PMID: 28359445
123. **Nachega JB,** Mills EJ, Uthman OA, Renaud F, Mofenson LM. Preconception ART and preterm birth: real effect or selection bias? *Lancet HIV*. 2017 Apr;4(4):e150-e151. doi: 10.1016/S2352-3018(17)30051-6. PMID: 28359445
124. Uthman OA, **Nachega JB,** Anderson J, Kanters S, Mills EJ, Renaud F, Essajee S,
125. Doherty MC, Mofenson LM. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. *Lancet HIV*.

2017 Jan;4(1):e21-e30. doi: 10.1016/S2352-3018(16)30195-3. Epub 2016 Nov 16.

126. **Nachega JB**, Uthman OA, Mofenson LM, Anderson JR, Kanters S, Renaud F, Ford N, Essajee S, Doherty MC, Mills EJ. Safety of Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Regimens in Pregnancy for HIV-Infected Women and Their Infants: A Systematic Review and Meta-Analysis. *J Acquir Immune Defic Syndr*. 2017 Mar 10. PMID: 2829105
Byabene AK, Fortes-Déguénonvo L, Niang K, Manga MN, Bulabula ANH,
127. **Nachega JB**, Seydi M. Optimal antiretroviral therapy adherence as evaluated by CASE index score tool is associated with virological suppression in HIV-infected adults in Dakar, Senegal. *Trop Med Int Health*. 2017 Jun;22(6):776-782.
128. Haberer JE, Sabin L, Amico KR, Orrell C, Galárraga O, Tsai AC, Vreeman RC, Wilson I, Sam-Agudu NA, Blaschke TF, Vrijens B, Mellins CA, Remien RH,
129. Weiser SD, Lowenthal E, Stirratt MJ, Sow PS, Thomas B, Ford N, Mills E, Lester R, **Nachega JB**, Bwana BM, Ssewamala F, Mbuagbaw L, Munderi P, Geng E, Bangsberg DR. Improving antiretroviral therapy adherence in resource-limited settings at scale: a discussion of interventions and recommendations. *J Int AIDS Soc*. 2017 Mar 22;20(1):1-15. doi: 10.7448/IAS.20.1.21371. PMID: 2836456
Kanters S, Park JJ, Chan K, Socias ME, Ford N, Forrest JI, Thorlund K, **Nachega**
131. **JB**, Mills EJ. Interventions to improve adherence to antiretroviral therapy: a systematic review and network meta-analysis. *Lancet HIV*. 2017 Jan;4(1):e31-e40.
132. Omaswa F, Kiguli-Malwadde E, Donkor P, Hakim J, Derbew M, Baird S, Frehywot S, Gachuno OW, Kamiza S, Kibwage IO, Mteta KA, Mulla Y, Mullan F, **Nachega JB**, Nkomazana O, Noormohamed E, Ojooome V, Olalaye D, Pillay S, Sewankambo NK, de Villiers M. Medical Education Partnership Initiative gives birth to AFREhealth. *Lancet Glob Health*. 2017 Oct;5(10):e965-e966
133. **Nachega JB**, Sam-Agudu NA, Mofenson LM, Schechter M, Mellors JW. e966Achieving Viral Suppression in 90% of People Living with HIV on Antiretroviral Therapy in Low- and Middle-Income Countries: Progress, Challenges, and Opportunities. *Clin Infect Dis*. 2018. Jan 8. doi: 10.1093/cid/ciy008. [Epub ahead of print] No abstract available. PMID: 29324994.
134. Fatti G, Jackson D, Goga AE, Shaikh N, Eley B, **Nachega JB**, Grimwood A. The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: an operational research study in South Africa *J Int AIDS Soc*. 2018 Feb;21 Suppl 1. doi:10.1002/jia2.25041.PMID: 29485714
135. Katoto PDMC, Thienemann F, Bulabula ANH, Esterhuizen TM, Murhula AB, Lunjwire PPM, Bihehe DM, **Nachega JB**. Prevalence and Risk Factors of Metabolic Syndrome in HIV-Infected Adults at Three Urban Clinics in a Post-Conflict Setting, Eastern Democratic Republic of Congo. *Trop Med Int Health*. 2018 May 12. PMID: 29752857
136. Byamungu LN, du Preez K, Walters E, **Nachega JB**, Schaaf HS. Timing of HIV

- diagnosis in children with tuberculosis managed at a referral hospital in Cape Town, South Africa. *Int J Tuberc Lung Dis*. 2018 May 1;22(5):488-495. PMID: 29663952
137. Fatti G, Jackson D, Goga AE, Shaikh N, Eley B, **Nachega JB**, Grimwood A. The effectiveness and cost-effectiveness of community-based support for adolescents receiving antiretroviral treatment: an operational research study in South Africa. *J Int AIDS Soc*. 2018 Feb;21 Suppl 1. doi: 10.1002/jia2.25041. PMID: 29485714
 138. **GBD Tuberculosis Collaborators**. Global, regional, and national burden of tuberculosis, 1990-2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study. *Lancet Infect Dis*. 2018 Dec;18(12):1329-1349. doi:10.1016/S1473-3099(18)30625-X.
 139. **GBD 2017 SDG Collaborators**. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):2091-2138.
 140. **GBD 2017 Population and Fertility Collaborators**. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1995-2051.
 141. **GBD 2017 Causes of Death Collaborators**. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1736-1788
 142. **GBD 2017 Mortality Collaborators**. Global, regional, and national age-sex-specific mortality and life expectancy, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov 10;392(10159):1684-1735.
 143. Nakimuli-Mpungu E, Musisi S, Wamala K, Okello J, Ndyababangi S, Birungi J, Nanfuka M, Etukoit M, Mojtabei R, **Nachega J**, Harari O, Mills E. Recruitment and Baseline Characteristics of Participants in the Social, Emotional, and Economic Empowerment Through Knowledge of Group Support Psychotherapy Study (SEEK-GSP): Cluster Randomized Controlled Trial. *JMIR Res Protoc*. 2019
 144. Hansoti B, Kalbarczyk A, Hosseinipour MC, Prabhakaran D, Tucker JD, **Nachega J**, Wallis L, Stiles JK, Wynn A, Morroni C. Global Health Mentoring Toolkits: A Scoping Review Relevant for Low- and Middle-Income Country Institutions. *Am J Trop Med Hyg*. 2019 Jan;100(1_Suppl):48-53
 145. Soomro N, Fitzgerald G, Seeley J, Schatz E, **Nachega JB**, Negin J. Comparison of Antiretroviral Therapy Adherence Among HIV-Infected Older Adults with Younger

Adults in Africa: Systematic Review and Meta-analysis. *AIDS Behav.* 2019 Feb;23(2):445-458.

146. Mateo-Urdiales A, Johnson S, Smith R, **Nachega JB**, Eshun-Wilson I. Rapid initiation of antiretroviral therapy for people living with HIV. *Cochrane Database Syst Rev.* 2019 Jun 17;6:CD012962
147. Gonese E, Kilmarx PH, van Schalkwyk C, Grebe E, Mutasa K, Ntozini R, Parekh B, Dobbs T, Duong Pottinger Y, Masciotra S, Owen M, **Nachega JB**, van Zyl G, Hargrove JW. Evaluation of the Performance of Three Biomarker Assays for Recent HIV Infection Using a Well-Characterized HIV-1 Subtype C Incidence Cohort. *AIDS Res Hum Retroviruses.* 2019 May 13
148. Fatti G, Grimwood A, **Nachega JB**, Nelson JA, LaSorda K, Zyl GV, Grobbelaar N, Ayles H, Hayes R, Beyers N, Fidler S, Bock P; HPTN 071 (PopART) study team. Better Virological Outcomes amongst People Living with HIV Initiating Early Antiretroviral Treatment (CD4 counts \geq 500 cells/ μ L) in the HPTN 071 (PopART) Trial in South Africa. *Clin Infect Dis.* 2019 Mar 16.
149. Bulabula ANH, Nelson JA, Musafiri EM, Machezano R, Sam-Agudu NA, Diacon AH, Shah M, Creswell J, Theron G, Warren RM, Jacobson KR, Chirambiza JP, Kalumuna D, Bisimwa BC, Katoto PDMC, Kaswa MK, Birembano FM, Kitete L, Grobusch MP, Kashongwe ZM, **Nachega JB**. Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012-2017: A Retrospective Province-Wide Cohort Study. *Clin Infect Dis.* 2019 Feb 13
150. **Nachega JB**, Ndamase S, Chiang N, Chivese T, Jennings Mayo-Wilson L, Sam-Agudu NA, Burke JG, Knowlton AR, Cotton MF, Theron GB, Serafini G, Lester RT, Fatti G, Grimwood A, Skinner D. Text messaging and community-based directly observed antiretroviral therapy by patient-nominated treatment supporters to improve antiretroviral adherence among pregnant women living with HIV in South Africa: a feasibility assessment. Submitted to Patient Preference and Adherence.

List of Published Work also available in MyBibliography:

<http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48313639/?sort=date&direction=ascending>

2. Book Chapters

1. Chaisson RE and **Nachega JB**. Editors: Warrell DA, Cox TM, Firth JD. Chapter. 6.7.25: Tuberculosis. In *Oxford Textbook of Medicine*. Oxford University Press. 5th Edition, 2010. Updated in 2012.
<http://oxfordmedicine.com/view/10.1093/med/9780199204854.001.1/med-9780199204854>

2. **Nachega JB**, Colebunders B., Apers L. Editors: Zumla A, Schaaf H.S. Tuberculosis Preventive Therapy in the Developed and Developing Countries. In *Tuberculosis, A Comprehensive Clinical Reference*. Elsevier Press. 1st Edition, 2009.
http://www.amazon.com/dp/B0040SYIOW/ref=rdr_kindle_ext_tmb
3. **Nachega JB** and Maartens G, Editors: Zumla A, Schaaf HS. Clinical Manifestations of Tuberculosis. in *Tuberculosis, A Comprehensive Clinical Reference*. Elsevier Press. 1st Edition, 2009.
http://www.amazon.com/dp/B0040SYIOW/ref=rdr_kindle_ext_tmb
4. **Nachega JB and Papa Salif-Sow**. *Integrated Management of Adolescent and Adult Illness District Clinician Manual (IMAI)*. Guidelines for the management of common illnesses with limited resources. HIV and Opportunistic Infections Chapter. Editors: WHO. Publication date: 2011. ISBN: 9789241548281 (vol. 1). ISBN 9789241548290 (vol.2) <http://www.who.int/hiv/pub/imai/imai2011/en/>

3. Selected 2016-to Present Invited National and International Presentations

1. Invited Speaker: The NIH-Sponsored workshop preceding **the 21st International AIDS Conference 2016 workshop on Alcohol and HIV/AIDS in Durban, South Africa, 18 July 2016**. www.aids2016.org
2. Invited co-Chair for the oral abstract session at the 21st International AIDS Conference, to be held in Durban, South Africa, July 19, 2016. Session **Title: Clubs, Cash and Caregivers: Impact on HIV Treatment Adherence and Retention**. www.aids2016.org
3. Invited co-Chair for a **special session symposium at the 21st International AIDS Conference, to be held in Durban, South Africa, July 20, 2016**. Session Title: **Optimizing the HIV care continuum through implementation science research**. www.aids2016.org
4. Invited Plenary Speaker by the Midwest AIDS Training and Education partners (MATEP) in Chicago for **the 19th Annual MATEP HIV Treatment Update in Memory of Bonnie Lubin: Thursday, September 15, 2016**, Crowne Plaza Hotel Chicago Metro Downtown, 733 West Madison, Chicago, IL, USA. Title: Progress with the Global HIV Epidemic.
5. Invited Plenary Speaker: “Forum de Adesão”, August 11th and 12th, 2017, São Paulo, Brazil. Title: **“HIV Treatment as Prevention. Managing retention and adherence in long term treatment.”**
6. Invited Plenary Speaker: by the **“2nd International Center for Advanced Research and Training (ICART) Symposium August 17-19, 2018, Bukavu, Democratic**

Republic of the Congo. Title: “Update on HIV-Associated Cardiovascular Disease in sub-Saharan Africa”

7. Invited Plenary Speaker: **University of Bugando Medical School Annual Conference, Mwanza, Tanzania, October 22, 2017:** Title: “mHealth and Community-DOT to Improve MTCT Outcomes in South Africa, Uganda, Tanzania: The SANTU Trial.”

8. Invited Plenary Speaker: Nachega JB. **CME HIV Symposium of the University of Cincinnati, OHIO, USA, Saturday, March 24, 2018;** Theme: HIV Treatment Adherence Interventions Strategies.

9. Invited Plenary Speaker: **Forum de Adesão, May 18th-19th, 2018, São Paulo, Brazil.** Title: “Barriers to achieve 90% viral load suppression in low- and middle- income countries”

10. Invited Plenary Speaker: **Southern African HIV Clinicians Society Conference, October, 24-27, 2018, Gallagher Convention Centre, Midrand, Johannesburg, South Africa.** Title: “The implications of scarcer resources to reach the UNAIDS 90:90:90 Targets”

11. Invited Oral Abstract Chair, Session Titled: **HIV Care Continuum at the 2019 International Association of Provider in AIDS Care (IAPAC) Adherence Conference. WWW.IAPAC.ORG,** University of Maryland Sponsored Satellite Session, Monday, June 17-19, 2019, Miami, Florida, USA

12. Invited Plenary Speaker: **International AIDS Society 2019 Conference, Mexico City,** University of Maryland Sponsored Satellite Session, Monday, July 22, 2019. Title: “Evidence-Based Interventions for Prevention of Virologic Failure in Pregnant and Post-Partum Women in Low- and Middle-Income Countries”

13. Invited Expert Panel Speaker: **NIH Workshop on HIV-Associated Comorbidities, September 19-20, 2019, Bethesda, MD, USA.** Title: “HIV-Comorbidities in Low- and Middle-Income Countries.

14. Invited Plenary Speaker: **10th edition of the International Workshop on HIV & Aging, to be held on 10-11 October 2019 at the New Yorker Hotel in New York, NY, USA.** Title: “HIV and Aging in International Setting”

SERVICE

1. Service to School and University of Pittsburgh

Years	Activity Description	Position
2012 to present	Coordination of Pitt Center for Global Health and Stellenbosch University. Provide opportunities for Pitt faculty and students with opportunities for research and training in South Africa.	Pitt Liaison Faculty in South Africa
2013 to present	Developing research capacity at University Catholic of Mozambique Pitt site by mentoring trainees in Beira or while they are rotating at Stellenbosch University through the NIH/FIC Funded Pitt-Mozambique HIV Research Training Program (PI: Harrison L.)	Pitt Faculty Mentor for Trainees from Mozambique
2017 to present	Pitt Global Health Steering Committee Member	Member
2019 to present	Appointment to the School Diversity Committee	Member

2. Service to Field of Scholarship

a. Editorial Boards, Editorships

Date	Position	Journal
2008 to present	Editorial Board	<i>The Open AIDS Journal</i>
2008 to present	Associate Editor	<i>Journal of International Association of Providers of AIDS Care (JIAPAC)</i>
2009	Guest Editor	<i>New England Journal of Medicine</i>
2010 to present	Associate Editor	<i>BMC Infectious Diseases</i>
2010 to 2015	Editorial Board	AIDS
2012 to present	Associate Editor	<i>BMC Public Health</i>
2016 to present	Associate Editor	<i>BMC Public Health</i>
2016 to present	Associate Editor	<i>Journal of Acquired Immunodeficiency Syndrome (JAIDS)</i>

b. Manuscript and Other Document/Publication Review

1. Reviewer, *The American Journal of Tropical Medicine and Hygiene*
2. Reviewer, *The International Journal of Tuberculosis and Lung Disease (ITJLD)*
3. Reviewer, *Clinical Infectious Diseases (CID)*
4. Reviewer, *JAMA*
5. Reviewer, *New England Journal of Medicine (NEJM)*
6. Reviewer, *Journal of Acquired Immunodeficiency Syndrome (JAIDS)*
7. Reviewer, *AIDS and Behavior*
8. Reviewer, *AIDS Care*
9. Reviewer, South African Medical Research Council, HIV/TB Research Grant Proposals
10. Reviewer, *PLoS Medicine*
11. Reviewer, *The Lancet*
12. Reviewer, *HIV Therapy*
13. Reviewer, *Social Science Medicine*
14. Reviewer, *HIV Clinical Trials*
15. Reviewer, *The Lancet HIV*

c. Study Sections, Review Panels, and Advisory Boards

A. NIH Study Sections

Date	Position	Organization and Nature of Activity
November 8, 2011	Study Section Expert Panel Member	NIH. RFA MH-12-060 and 12-061: “Promoting Engagement in Care and Timely Antiretroviral Initiation Following HIV Diagnosis”
June 16-17, 2014	Study Section Expert Panel Member	NIH. PAR 14-028: “mHealth: Technology & Outcomes in Low and Middle-Income Countries”
July 30, 2014	Study Section Expert Panel Member	NIH. RFA-AI-14-009: “USA-South Africa Collaborative Bio-Medical Research”
June 11-12, 2015	Study Section Expert Panel Member	NIH. PAR 14-028: “mHealth: Technology & Outcomes in Low and Middle-Income Countries”
July 7-8, 2015	Study Section Expert Panel Member	NIH. RFA-AI-14-071: Innovative Measures of Oral Medication Adherence for HIV Treatment and Prevention (R01)

Date	Position	Organization and Nature of Activity
October 26-27, 2015	Study Section Expert Panel Member	NIH. RFA-AI-15-020: “NIH PEPFAR Collaboration on Implementation Science for HIV”
July 11-12/2017	Study Section Expert Panel Member	NIH/NIAID; AIDS Clinical Studies and Epidemiology (ACE) Study Section, Courtyard Long Beach, Long Beach, CA, USA
June 28/2017	Study Section Expert Panel Member	NIH/FIC: 2017/08 ZRG1 IDM-U (56) R PAR-16-407: Emerging Epidemic Virus Research Training, National Institutes of Health, Bethesda, MD, USA
July 31-August 1/2018	Study Section	NIH/NIAID, AIDS Clinical Studies and Epidemiology (ACE) Study Section, Mayflower Hotel, Washington, DC, USA

B. Other Scientific Expert Panels

Date	Position	Organization and Nature of Activity
2001-2002	Consultant	World Bank: Multi-Sectoral Response Against HIV/AIDS in sub-Saharan Africa, Washington DC, USA
Oct 11-12, 2001	Ad Hoc Expert Panel Member	UNDP/World Bank/WHO: Special Program for Research and Training in Tropical Diseases (TDR): Meeting on International Coordination for TB Clinical Trial Working Group, Geneva, Switzerland
Oct 14, 2005	Ad Hoc Expert Panel Member	European Developing Countries Clinical Trial Partnership (EDCTP): Tuberculosis and HIV/AIDS Grant Applications Review Panel, The Hague, The Netherland
May 16, 2008	Ad Hoc Expert Panel Member	European Developing Countries Clinical Trial Partnership (EDCTP): Tuberculosis and HIV/AIDS Grant Applications Review
Oct 26-28, 2010	Ad Hoc Expert Panel Member	Evidence Review Meeting on HIV-related Opportunistic Infections, Cancers within the Integrated Management of Adults and Adolescent Illness (IMAI) District Clinical Manual, Geneva, Switzerland

Date	Position	Organization and Nature of Activity
Dec 14-15, 2010	Consultant	WHO/PEPFAR; Consultation on Transformative Scale Up of Medical, Nursing and Midwifery Education in Africa, Geneva, Switzerland
April 10, 2011	Ad Hoc Expert Panel Member	US/CDC: Conducting Public Health Research Through the Field Epidemiology and Laboratory Training Programs (FETPs/FELTPs); Atlanta, GA, USA
Aug 11-12, 2011	Ad Hoc Expert Panel Member	HIV Drug Resistance Research Network (HIVResNet) Expert Advisory Meeting on Early Warning Indicator for Antiretroviral Therapy Treatment Failure and Drug Resistance. Geneva, Switzerland
Nov 14-18, 2011	Ad Hoc Expert Panel Member	European Union (EU) Commission to review research proposals submitted for the call: FP7-Health-2012-Innovation-1, Brussels, Belgium
Oct 10-11, 2012	Ad Hoc Expert Panel Member	Collaborative HIV and Anti-HIV Drug Resistance Network (CHAIN) and WHO HIVResNet; Consultation on Implications of HIV Drug Resistance on Choice of 1 st and 2 nd Line Therapies in resource-limited settings, Hotel Warwick, London, UK
May 2-4, 2012	Ad Hoc Expert Panel Member	WHO: Consultation Meeting on the Strategic Use of Antiretroviral Therapy, Geneva, Switzerland
2013 to present	Working Group Member	NIH-NIAID AIDS Clinical Trial Group (ACTG)'s Tuberculosis Host-Directed Therapy (HDT) Working Group and Lead HIV Investigator
Sept 24-26, 2014	Ad Hoc Expert Panel Member	WHO: Scoping Consultation on Simplifying Care Models for People Living with HIV, Geneva, Switzerland
June 16-19, 2015	Ad Hoc Expert Panel Member	WHO: The 2015 Antiretroviral Therapy Consolidated - Operational Guidelines Development Group Meeting, Chavannes-de-Bogis, Switzerland.

Date	Position	Organization and Nature of Activity
July 18, 2015	Ad Hoc Expert Panel Member	Bill and Melinda Gates Foundation: Expert HIV Consultant Meeting to focus on Intervention Strategies to Improve Linkage to Care, Retention and Adherence to Antiretroviral Therapy in Resource-Limited Settings, Vancouver, Canada
Sept 28-29, 2015	Ad Hoc Expert Panel Member	WHO: Global Competency in Clinical Research, Hotel de Alpes, Geneva, Switzerland
Oct 28, 2015	Ad Hoc Expert Panel Member	US CDC: Special Emphasis Panel (SEP) to determine merit of response to a funding announcement in area of conducting global public health research. Video-Conference Meeting.
November, 2017 to present	Member-at-Large	AIDS Clinical Trial Group (ACTG) Scientific Agenda Steering Committee (SASC) supported by US National Institutes of Health, National Institutes of Allergy and Infectious Diseases (NIAID)

C. Advisory Boards

Date	Position	Organization and Nature of Activity
2008-12	Board Member	International Association of Providers in AIDS Care, Washington DC, USA. www.iapac.org
2010-12	Board Member	Child Health Foundation, Columbia, MD, USA www.childhealthfoundation.org
2012 to present	Board Member	The Area Health Education Center (AHEC) Project. Stellenbosch University, Cape Town, South Africa. http://www.suncep.sun.ac.za/SBI/AHEC_tutor.html

d. Leadership in Scholarly and Professional Organizations and Honorary Societies

Date	Position	Organization
1999 to present	Member	Infectious Diseases Society of America (IDSA). www.idsociety.org
1999 to present	Member	HIV Medicine Association (HIVMA) of IDSA. http://www.hivma.org/Home.aspx
1999 to present	Member	American Society of Tropical Medicine and Hygiene (ASTMH). www.astmh.org
2003 to present	Chair of the Annual Meeting Scientific Program Committee: HIV and co-Infections Section	American Society of Tropical Medicine and Hygiene (ASTMH). www.astmh.org
2007 to present	Member	International AIDS Society (IAS). www.iasociety.org
2008 to present	Member	International Association of Providers in AIDS Care. www.iapac.org
2008 to present	Member Elect	Academy of Sciences of South Africa. www.assaf.co.za
2014 to present	Fellow Elect	Royal College of Physicians, Edinburgh, UK www.rcpe.ac.uk
2017 to present	Member-at-Large	AIDS Clinical Trial Group (ACTG) Scientific Agenda Steering Committee (SASC) supported by US National Institutes of Health, National Institutes of Allergy and Infectious Diseases (NIAID)
2018 to present	Fellow Elect	African Academy of Sciences https://aasciences.ac.ke/